Content
All Posts > Content under Healthcare
Tesaro Drops After Zejula Pricing, Competing PARPi Trial Miss
Article By:
The Fly
Read
Thursday, April 20, 2017 1:03 PM EDT
The shares of drug maker Tesaro are falling with two possible headwinds cited by analysts as the potential culprit, namely the pricing of its niraparib treatment and the disappointing trial results of another drug in the same therapeutic space.
Bull Of The Day: Inogen
Article By:
Zacks Investment Research
Read
Thursday, April 20, 2017 9:37 AM EDT
Shares of INGN have outperformed the Medical Instruments Industry YTD, with most of that outperformance coming in the last month and a half. INGN is up 14.8% so far this year while the industry is up only 4.7%.
In this article: INGN
Recent Stock Purchase II April 2017
Article By:
Keith Park
Read
Thursday, April 20, 2017 4:39 AM EDT
Mr. Market always has the last word and that sometimes stocks that I’m not considering in a particular month may suddenly become attractive once again because of a serious sell-off (usually after poor earning reports and guidance).
Ultragenyx Pharmaceutical Reports Positive Phase III Data For Their Kyowa Hakko Kirin-Partnered Drug
Article By:
Lorimer Wilson
Read
Thursday, April 20, 2017 2:54 AM EDT
Ultragenyx Pharmaceutical Inc. has reported clearly positive Phase III data for their Kyowa Hakko Kirin-partnered drug for X-linked hypophosphatemia, and now they plan to hustle that data package to regulators at the FDA and EMA.
In this article: RARE
Novartis Has Acquired An Exclusive License To Use Parvus Therapeutics’ Platform For Diabetes
Article By:
Lorimer Wilson
Read
Wednesday, April 19, 2017 11:00 PM EDT
The Novartis Institute of Biomedical Research now has the exclusive license to use Parvus Therapeutics’ platform for diabetes, coming in with an unspecified package of milestones, an upfront, research support and an equity stake to seal the deal.
In this article: NVS
Edge Therapeutics Announces $18 Million Registered Direct Offering Of Common Stock
Article By:
NASDAQ GlobeNewswire
Read
Wednesday, April 19, 2017 3:09 PM EDT
Edge Therapeutics, Inc., today announced that Edge has entered into a subscription agreement for the sale of shares of its common stock in a registered direct offering with Satter Medical Technology Partners, L.P.
In this article: EDGE
NurOwn Shows Potential In Preclinical Autism Model
Article By:
Jason Napodano
Read
Wednesday, April 19, 2017 1:20 PM EDT
BrainStorm’s next step in the development of NurOwn is to initiate a Phase 3 clinical study in the U.S. This will be a major milestone for the company and establish an important Catalyst for the shares once initiated.
In this article: BCLI
Abbott Tops Q1 Earnings On Strong EPD, Medical Device
Article By:
Zacks Investment Research
Read
Wednesday, April 19, 2017 12:51 PM EDT
Abbott Laboratories reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, 11.6% higher than the Zacks Consensus Estimate and up 17.1% year over year.
Sunshine Heart Announces Pricing Of $8.0 Million Underwritten Public Offering
Article By:
NASDAQ GlobeNewswire
Read
Wednesday, April 19, 2017 11:33 AM EDT
Sunshine Heart, Inc. announced today the pricing of an underwritten public offering of units for gross proceeds of $8.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Sunshine Heart.
In this article: SSH
Nivalis Therapeutics, Inc. Shares Climb Up On Announcement Of Merger
Article By:
TickerTV
Read
Wednesday, April 19, 2017 11:26 AM EDT
NVLS opened trading yesterday at $2.75 which was down from the previous day’s trading close of $2.77. NVLS closed trading yesterday at $2.64 and spiked up after market to $3.20, equivalent to a 21% increase from the closing price.
In this article: NVLS
Why Ligand Pharmaceuticals Is A Good Long-Term Investment Opportunity
Article By:
Arie Goren
Read
Wednesday, April 19, 2017 10:40 AM EDT
Ligand is a fast growing biotech company with a distinctive business model. Investors can participate in the high-promising biotech industry by investing in LGND stock with lower-risk than investing in a typical high-growth biotechnology company.
Abbott Laboratories Q1 Revenue Surges 30% As Medical Devices Lead
Article By:
Lorimer Wilson
Read
Wednesday, April 19, 2017 8:50 AM EDT
Abbott Laboratories early Wednesday posted much better than expected first quarter earnings results, led by huge growth in its medical devices unit that was bolstered by a recent acquisition.
In this article: ABT